BioCentury

8:00 AM GMT, Dec 23, 2013
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Kyprolis carfilzomib: Phase II data

Researchers at the University of Torino reported data from an open-label, European Phase II trial in 58 patients with newly diagnosed MM showing that IV Kyprolis plus cyclophosphamide and dexamethasone led a 2-year PFS rate of 76% and a 2-year OS

Read the full 410 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.